Clinical Trial on the Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
NCT ID: NCT06950645
Last Updated: 2025-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
100 participants
INTERVENTIONAL
2024-03-27
2026-03-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of this study is to evaluate the safety of investigational vaccine in healthy adults and children, as well as its safety tolerability, and immunogenicity in healthy infants.
The study will be an open-label observation in adults and children, and a randomized, double-blind, placebo-controlled clinical trial in infants.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
NCT06967272
Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old
NCT06350058
Phase II Clinical Trial of the Inactivated Rotavirus Vaccine
NCT06080906
A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)
NCT00953056
Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old
NCT00439660
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will enroll 100 participants, consisting of 20 adults aged 18-59 years, 20 children aged 2-6 years, and 60 infants aged 6-12 weeks. Participants will be enrolled sequentially, starting with adults, followed by children, and then infants. Enrollment for the subsequent group will begin after a 14-day safety observation period and confirmation of acceptable safety in the preceding group. Adult and child participants will receive the investigational vaccine in an open-label manner. The infants will be enrolled into two cohorts of 30 participants each: a low-dose cohort and a high-dose cohort. Within each cohort, the infants will be randomly assigned to two groups at a ratio of 2:1 and will receive either the investigational vaccine or a placebo in a double-blind manner. The immunization schedule for both the vaccine and placebo consists of three doses administered at 28-day intervals.
Adverse events (AE) will be collected for all participants until 42 days after the last dose vaccination. Stool samples will be collected after each vaccination to detect vaccine strain shedding among infant participants. Serious adverse events (SAE) will be observed for 6 months from the last dose for adults and children or 12 months for infants. Blood samples from the infants will be collected at predetermined times to evaluate the immunogenicity of the investigational vaccine.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adult
The experimental vaccine will be administered in three doses, with a 28-day interval between each dose.
Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Children
The experimental vaccine will be administered in three doses, with a 28-day interval between each dose
Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Infants low-dose 1
They will receive three low-dose experimental vaccine in a double-blind setting, with a 28-day interval between each dose.
Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
Infants low-dose 2
They will receive three doses of the placebo in a double-blind setting, with a 28-day interval between each dose
Placebo
Placebo of experimental vaccine for infants three doses administered orally
Infants high-dose 1
They will receive three high-dose experimental vaccine in a double-blind setting, with a 28-day interval between each dose
Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Infants high-dose 2
They will receive three doses of the placebo in a double-blind setting,with a 28-day interval between each dose
Placebo
Placebo of experimental vaccine for infants three doses administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
Placebo
Placebo of experimental vaccine for infants three doses administered orally
Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
Placebo
Placebo of experimental vaccine for infants three doses administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Provide legal identification.
3. Male or female, aged 6 to 12 weeks, or 2 to 6 years, or 18 to 59 years, and in good health.
4. Fertile participants have no plans for pregnancy from the time of signing the informed consent form until 3 months after the last dose of the study vaccine and agree to use effective contraception, and have no plans for sperm or egg donation.
Exclusion Criteria
2. Current diarrhea or vomiting, or other gastrointestinal diseases, or having experienced gastroenteritis or any acute illness or acute exacerbation of chronic disease within the past 7 days, or those currently using antibiotics or antiviral therapy.
3. History of intussusception or chronic gastrointestinal disease, including gastrointestinal congenital anomalies that can easily cause intussusception (e.g., Meckel's diverticulum).
4. For infant and pediatric participants: congenital malformations or developmental disabilities, genetic defect diseases, severe malnutrition, or severe chronic diseases (such as Down syndrome, diabetes, sickle cell anemia, neurological disorders, Guillain-Barré syndrome); For adult participants: uncontrolled chronic diseases or severe disease history, including but not limited to cardiovascular diseases (such as drug-uncontrolled hypertension, i.e., systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), hematologic diseases, hepatic and renal diseases, gastrointestinal diseases, respiratory diseases, malignant tumors, history of major organ transplantation, or any other disease or medical condition that the investigator believes may interfere with the trial results.
5. Presence of autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection).
6. Household members living with the participant are in an immunodeficient or immunosuppressed state or are currently/soon to be receiving immunosuppressive therapy, cytotoxic therapy, etc.
7. Presence of coagulation dysfunction (such as deficiency of coagulation factors, abnormal platelets).
8. Received \>14 days of immunosuppressive therapy or other immunomodulatory therapy, cytotoxic therapy within the past 6 months (for adult and pediatric participants) or since birth (for infant participants), or planned to receive such treatment during the study period.
9. Chronic alcoholism \[weekly alcohol consumption \>14 drinking units (1 drinking unit = 14 grams of 100% alcohol = 360 mL beer, or 150 mL wine, or 45 mL distilled spirits/liquor)\] or history of drug abuse (repeated, excessive use of narcotic drugs, psychotropic substances, volatile organic solvents, etc.) (for adult participants).
10. Suffering from/having suffered from severe neurological diseases (epilepsy, convulsions or seizures) or mental illness, or having a family history of the same.
11. Received immunoglobulin or other blood products within 6 months before receiving the trial vaccine (for adult and pediatric groups) or in the past (for infant group), or planned to receive such treatment during the study period.
12. Received other investigational drugs or vaccines within the past 30 days, or planned to receive such drugs or vaccines during the study period.
13. Received live attenuated vaccines or COVID-19 vaccines within the past 14 days, or subunit or inactivated vaccines and other process vaccines within the past 7 days.
14. Had axillary temperature ≥38.0℃ within the past 3 days.
15. On the day planned for vaccination with the trial vaccine, having a fever with axillary temperature \>37.0℃.
16. Clinical laboratory tests showing laboratory abnormalities beyond the reference range that are clinically significant (for adult and pediatric groups):
* Hematology test indicators: white blood cell count, hemoglobin, platelet count.
* Biochemical blood test indicators: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), creatinine (CR), fasting blood glucose (Glu).
* Urinalysis test indicators: urine protein (PRO).
17. Fertile women with positive urine pregnancy test or breastfeeding.
18. Currently or planning to participate in other vaccine or drug clinical trials.
19. Any other factors that the investigator deems unsuitable for participation in the clinical trial.
1. Previously received rotavirus vaccine.
2. History of rotavirus infection.
3. Neonatal gestational age \<37 weeks or ≥42 weeks.
4. Birth weight \<2500g.
5. History of difficult labor, resuscitation from asphyxia, or neurological damage at birth.
6 Weeks
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinovac Life Sciences Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hebei Provincial Center for Disease Control and Prevention
Shijiazhuang, Hebei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO-RV-1001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.